InnSight Technology has filed a notice of an exempt offering of securities to raise $3 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, InnSight Technology is raising up to $3 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About InnSight Technology
InnSight Technology is a medical device company focused on advancing tear fluid analytics to improve the diagnosis and management of eye and systemic diseases. Based on proprietary core technology, the company develops point-of-care solutions that provide quantitative measurements of tear fluid biomarkers within minutes, enabling more standardized and objective treatment decisions. InnSights primary focus is on non-invasive collection and analysis of tear fluid to support diagnostics for conditions such as dry eye and other hard-to-detect ocular and systemic disorders. Positioned as an innovative tear fluid analytics leader, the company emphasizes translational research to move cutting-edge biosensor technology from the laboratory into clinical practice. Through its commitment to rapid, objective biomarker testing, InnSight Technology aims to enhance clinical care by giving healthcare providers more precise, data-driven tools for evaluating disease and guiding therapy.
To learn more, visit https://www.innsightech.com/
LinkedIn: https://www.linkedin.com/company/innsight-tech-inc
Contact:
Leanne Labriola, President
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.